ClinicalTrials.gg
RecruitingNCT07623616Updated Jun 3, 2026

A Phase 2 Clinical Study of Ziftomenib in Patients With Relapsed or Refractory NPM1-Mutated Acute Myeloid Leukemia

A Phase 2 interventional study of ziftomenib in Acute Myeloid Leukemia (AML), sponsored by Kyowa Kirin Co., Ltd.. Recruiting at 20 sites in Japan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-03.

Sponsored by Kyowa Kirin Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.
Phase
Phase 2
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This is the first study to administer ziftomenib to Japanese patients. In this study, the efficacy, safety, and pharmacokinetics of ziftomenib will be evaluated in patients with relapsed or refractory NPM1-mutated acute myeloid leukemia

02

Conditions studied

  • Acute Myeloid Leukemia (AML)
03

In context

Leukemia, Myeloid, Acute

3,667 studies on the registry are indexed under Leukemia, Myeloid, Acute; 816 are open to participants now.

This study's planned enrollment of 6 is below the median of 40 across 3,005 interventional studies indexed under Leukemia, Myeloid, Acute.

Browse Leukemia, Myeloid, Acute studies →

Lead sponsor

Kyowa Kirin Co., Ltd. is the lead sponsor of 159 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntary written and willingness to comply with all study procedures
  • Age ≥ 18 years
  • Confirmed diagnosis of acute myeloid leukemia (AML)
  • Patients with R/R AML with NPM1-m
  • No available standard of care expected to provide clinical benefit, ineligible for or declined standard therapy.
  • performance status 0-2.
  • White blood cell count ≤ 30,000/mm³ at screening (hydroxyurea permitted for cytoreduction).
  • Adequate organ function according to protocol requirements.
  • Women of must be willing to use a highly effective method of throughout the study and for at least 187 days after the last dose of study treatment.
  • Males with female partners of childbearing potential must agree to use a highly effective method of contraception throughout the study and for at least 97 days after the last dose of study treatment.

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of acute promyelocytic leukemia.
  • Donor lymphocyte infusion \< 30 days prior to study entry.
  • Clinically active central nervous system (CNS) leukemia.
  • Prior hematopoietic stem cell transplantation () without adequate hematologic recovery.
  • Active Grade ≥ 2 acute or moderate/severe chronic graft-versus-host disease.
  • Prior treatment with a menin inhibitor.
  • Receipt of chemotherapy, immunotherapy, radiotherapy, or therapy within 14 days or 5 half-lives prior to first dose.
  • Unresolved toxicities from prior therapy > Grade 1.
  • Requirement for strong inducers.
  • Active or uncontrolled infection, including , , or .
  • Conditions predisposing to serious or life-threatening infection or significant immunodeficiency.
  • Cardiovascular disease or > 480 ms.
  • Interstitial lung disease.
  • Major surgery within 4 weeks prior to first dose.
  • Women who are pregnant or lactating
  • Any medical, psychiatric, or social condition that may interfere with study participation or safety, or that makes the patient unsuitable in the investigator's judgment.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (estimated)

Study arms

  • Experimental
    ziftomenib

    Oral adminitration once daily

    Drug: ziftomenib

Interventions

06

What researchers measure

Primary outcomes

  1. CR+CRh rate

    Time frame: Best overall response assessed every 28 days from first dose until disease progression or withdrawall, an average of 16weeks

Secondary outcomes

  1. MRD-negative CR+CRh (CR+CRhMRD-) rate

    Time frame: Best overall response assessed every 28 days from first dose until disease progression or withdrawall, an average of 16weeks

  2. CR rate

    Time frame: Best overall response assessed every 28 days from first dose until disease progression or withdrawall, an average of 16weeks

  3. MRD-negative CR rate

    Time frame: Best overall response assessed every 28 days from first dose until disease progression or withdrawall, an average of 16weeks

  4. CRc (CR+ CRh + CRi) rate

    Time frame: Best overall response assessed every 28 days from first dose until disease progression or withdrawall, an average of 16weeks

  5. MRD-negative CRc (CRcMRD-) rate

    Time frame: Best overall response assessed every 28 days from first dose until disease progression or withdrawall, an average of 16weeks

  6. ORR (CR + CRh + CRi + MLFS + PR)

    Time frame: Best overall response assessed every 28 days from first dose until disease progression or withdrawall, an average of 16weeks

  7. Transfusion independence rate

    Time frame: From the day after first dose through the last dose before initiation of subsequent therapy (including hematopoietic stem cell transplantation)l, an average of 16weeks

  8. Duration of CR+CRh

    Time frame: Every 28 days from first dose until disease progression or withdrawall, an average of 16weeks

  9. Time to CR+CRh

    Time frame: Every 28 days from first dose until disease progression or withdrawall, an average of 16weeks

  10. Time to CR

    Time frame: Every 28 days from first dose until disease progression or withdrawall, an average of 16weeks

  11. Time to CRc

    Time frame: Every 28 days from first dose until disease progression or withdrawall, an average of 16weeks

  12. Time to CR, CRh, Cri, MLFS or PR

    Time frame: Every 28 days from first dose until disease progression or withdrawall, an average of 16weeks

  13. EFS

    Time frame: Every 28 days from first dose until disease progression or withdrawall, an average of 16weeks

  14. OS

    Time frame: During the treatment and every 90 days after study treatment completion (approximately up to 1 year after study treatment completion)

  15. Incidence and severity of adverse events

    Time frame: During treatment and up to approximately 28 days after treatment discontinuation

  16. Incidence of serious adverse events

    Time frame: During treatment and up to approximately 28 days after treatment discontinuation

  17. Death during treatment with ziftomenib

    Time frame: During the treatment

  18. Discontinuation of ziftomenib due to adverse events

    Time frame: During the treatment

  19. Clinically significant changes in clinical laboratory values, vital signs, and ECG parameters

    Time frame: During treatment and up to end of the treatment assessment

  20. Clinically significant decrease in ECOG PS

    Time frame: During treatment and up to end of the treatment assessment

  21. Area under the plasma drug concentration time curve over a dosing interval (AUC0-τ)

    AUC0-τ of ziftomenib and its metabolites

    Time frame: Cycle 1 Day 1, and Cycle 2 Day 1 (each cycle is 28 days)

  22. Maximum plasma concentration (Cmax)

    Cmax of ziftomenib and its metabolites

    Time frame: Cycle 1 Day 1, and Cycle 2 Day 1 (each cycle is 28 days)

  23. Time to observed maximum plasma concentration (Tmax)

    Tmax of ziftomenib and its metabolites

    Time frame: Cycle 1 Day 1, and Cycle 2 Day 1 (each cycle is 28 days)

07

Study locations

15 of 20 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The datasets generated and/or analyzed during the study sponsored by Kyowa Kirin will be available in the Vivli repository, https://vivli.org/ourmember/kyowa-kirin/ as long as conditions of data disclosure specified in the policy section of the Vivli website are satisfied.

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07623616
Responsible party
Sponsor
First posted
Jun 3, 2026
Start date
Apr 23, 2026
Primary completion
Mar 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Jun 3, 2026

Study contacts

Kyowa Kirin, Inc.
Contact
kkd.clintrial.82@kyowakirin.com
1-609-919-1100
Kyowa Kirin Co., Ltd.
Contact
clinical.info.jp@kyowakirin.com

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ziftomenib

Start the discussion